These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 28671278)
21. Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells. Zhang T; Yin K; Niu X; Bai X; Wang Z; Ji M; Yuan B Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063201 [TBL] [Abstract][Full Text] [Related]
22. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700 [TBL] [Abstract][Full Text] [Related]
23. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer. Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096 [TBL] [Abstract][Full Text] [Related]
24. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. Hu Y; Duan J; Zhan Q; Wang F; Lu X; Yang XD PLoS One; 2012; 7(2):e31970. PubMed ID: 22384115 [TBL] [Abstract][Full Text] [Related]
25. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401 [TBL] [Abstract][Full Text] [Related]
26. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo. Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619 [TBL] [Abstract][Full Text] [Related]
27. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877 [TBL] [Abstract][Full Text] [Related]
28. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020 [TBL] [Abstract][Full Text] [Related]
29. Smart drug delivery of p-Coumaric acid loaded aptamer conjugated starch nanoparticles for effective triple-negative breast cancer therapy. Mariadoss AVA; Saravanakumar K; Sathiyaseelan A; Karthikkumar V; Wang MH Int J Biol Macromol; 2022 Jan; 195():22-29. PubMed ID: 34861273 [TBL] [Abstract][Full Text] [Related]
30. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo. Jalalian SH; Ramezani M; Abnous K; Taghdisi SM Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524 [TBL] [Abstract][Full Text] [Related]
31. Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer. Barlas FB; Olceroglu B; Ag Seleci D; Gumus ZP; Siyah P; Dabbek M; Garnweitne G; Stahl F; Scheper T; Timur S Cancer Med; 2024 Aug; 13(15):e70079. PubMed ID: 39118454 [TBL] [Abstract][Full Text] [Related]
32. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. Meng L; Yang L; Zhao X; Zhang L; Zhu H; Liu C; Tan W PLoS One; 2012; 7(4):e33434. PubMed ID: 22558072 [TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers. Abnous K; Danesh NM; Ramezani M; Charbgoo F; Bahreyni A; Taghdisi SM Expert Opin Drug Deliv; 2018 Nov; 15(11):1045-1052. PubMed ID: 30269603 [TBL] [Abstract][Full Text] [Related]
34. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2. Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158 [TBL] [Abstract][Full Text] [Related]
35. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823 [TBL] [Abstract][Full Text] [Related]
36. Targeted delivery of doxorubicin using a colorectal cancer-specific ssDNA aptamer. Li W; Chen H; Yu M; Fang J Anat Rec (Hoboken); 2014 Dec; 297(12):2280-8. PubMed ID: 25044297 [TBL] [Abstract][Full Text] [Related]
37. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. Cheng B; Gao F; Maissy E; Xu P Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604 [TBL] [Abstract][Full Text] [Related]
38. A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells. Bahreyni A; Yazdian-Robati R; Hashemitabar S; Ramezani M; Ramezani P; Abnous K; Taghdisi SM Int J Pharm; 2017 Jun; 526(1-2):391-399. PubMed ID: 28495579 [TBL] [Abstract][Full Text] [Related]
39. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide. Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345 [TBL] [Abstract][Full Text] [Related]
40. Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer. Bayrac AT; Akca OE; Eyidogan FI; Oktem HA J Biosci; 2018 Mar; 43(1):97-104. PubMed ID: 29485118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]